Literature DB >> 24715837

Relevance of health economics in breast cancer treatment: integration of economics in the management of breast cancer at the clinic level.

Volker R Jacobs1, Gerhard Bogner1, Christiane E Schausberger1, Roland Reitsamer1, Thorsten Fischer1.   

Abstract

Since the introduction of the diagnosis-related groups (DRG) system with cost-related and entity-specific flat-rate reimbursements for all in-patients in 2004 in Germany, economics have become an important focus in medical care, including breast centers. Since then, physicians and hospitals have had to gradually take on more and more financial responsibilities for their medical care to avoid losses for their institutions. Due to financial limitations of resources, most medical services have to be adjusted to correlating revenues, which results in the development of a variety of active measures to understand, steer, and optimize costs, resources and related processes for breast cancer treatment. In this review, the challenging task to implement microeconomic management at the clinic level for breast cancer treatment is analyzed from breast cancer-specific publications. The newly developed economic management perspective is identified for different stakeholders in the healthcare system, and successful microeconomic projects and future aspects are described.

Entities:  

Keywords:  Breast cancer; Costs of treatment; Health economics; Limited resources; Microeconomic solutions

Year:  2013        PMID: 24715837      PMCID: PMC3971800          DOI: 10.1159/000348370

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  27 in total

1.  Are Certified Breast Centers Cost-Effective?

Authors:  Matthias W Beckmann; Mayada R Bani; Christian R Loehberg; Thomas Hildebrandt; Michael G Schrauder; Stefanie Wagner; Peter A Fasching; Michael Patrick Lux
Journal:  Breast Care (Basel)       Date:  2009-08-14       Impact factor: 2.860

2.  Assessing the economic burden of breast cancer in a US managed care population.

Authors:  John J Barron; Ralph Quimbo; Prashant T Nikam; Mayur M Amonkar
Journal:  Breast Cancer Res Treat       Date:  2007-08-03       Impact factor: 4.872

3.  An economic model to reduce the cost of chemotherapy for gynecologic cancer.

Authors:  Volker R Jacobs; Jutta Thoedtmann; Bettina Brunner; Marion Kiechle
Journal:  Int J Fertil Womens Med       Date:  2004 Nov-Dec

4.  Physician-based active cost management of oncological therapies reducing pharmaceutical costs by 83.4% in two years without leaving standard of care.

Authors:  Volker R Jacobs; Jutta Thoedtmann; Uta Euler; Stefan Paepke; Thorsten Fischer; Nadia Harbeck; Marion Kiechle
Journal:  Onkologie       Date:  2005-08-29

5.  Limits on Medicare's ability to control rising spending on cancer drugs.

Authors:  Peter B Bach
Journal:  N Engl J Med       Date:  2009-01-27       Impact factor: 91.245

6.  Making or losing money with participation in clinical trials: a decision analysis.

Authors:  Volker R Jacobs
Journal:  Onkologie       Date:  2009-06-17

7.  Comparison of actual hospital costs versus DRG revenues for in-patient treatment of febrile neutropenia during adjuvant anthracycline plus/minus taxane-based chemotherapy for primary breast cancer.

Authors:  Volker R Jacobs; Stefanie C Mayer; Bernadette J Paessens; Rudolf Bernard; Nadia Harbeck; Marion Kiechle; Angela Ihbe-Heffinger
Journal:  Onkologie       Date:  2011-10-28

8.  Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007.

Authors:  Benjamin O Anderson; Cheng-Har Yip; Robert A Smith; Roman Shyyan; Stephen F Sener; Alexandru Eniu; Robert W Carlson; Edward Azavedo; Joe Harford
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

9.  Locally advanced breast cancer: treatment guideline implementation with particular attention to low- and middle-income countries.

Authors:  Nagi S El Saghir; Alexandru Eniu; Robert W Carlson; Zeba Aziz; Daniel Vorobiof; Gabriel N Hortobagyi
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

10.  Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality.

Authors:  Montserrat Vera-Llonch; Derek Weycker; Andrew Glass; Sue Gao; Rohit Borker; Angie Qin; Gerry Oster
Journal:  BMC Cancer       Date:  2011-06-15       Impact factor: 4.430

View more
  3 in total

1.  Health economics in breast cancer.

Authors:  Matthias W Beckmann; Michael P Lux
Journal:  Breast Care (Basel)       Date:  2013-03       Impact factor: 2.860

2.  Frequency and clinical characteristics of HER2 over-expressed breast cancer in Saudi Arabia: a retrospective study.

Authors:  Jamal Zekri; Ahmed Saadeddin; Hulayel Alharbi
Journal:  BMC Womens Health       Date:  2021-01-06       Impact factor: 2.809

3.  Considerations on the surgical treatment of Duct Carcinoma in Situ (DCIS) of the breast from DRG system perspective.

Authors:  Codruţ Cosmin Nistor-Ciurba; Marilena Cheptea
Journal:  Clujul Med       Date:  2014-01-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.